Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis

Gynecological Endocrinology

Volumn 29, Issue 12, 2013, Pages 1005-1014

  Serrano, Ana Julissa ^a   Begoña, Leire ^b   Anitua, Eduardo ^b   Cobos, Raquel ^c   Orive, Gorka ^a,b,d  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b Eduardo Anitua Foundation   (Spain)

^c Basque Health Service   (Spain)

^d BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

Author keywords

Amenorrhea; Menopause; Osteoporosis

Indexed keywords

ALENDRONIC ACID; CALCIUM; CORTICOSTEROID; PLACEBO; VITAMIN D; ZOLEDRONIC ACID;

BONE DENSITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ECONOMIC EVALUATION; FOLLOW UP; GASTROINTESTINAL DISEASE; HIP FRACTURE; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SECONDARY OSTEOPOROSIS; SPINE FRACTURE; STUDY DESIGN; SYSTEMATIC REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WRIST FRACTURE;

ADULT; AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HIP FRACTURES; HUMANS; IMIDAZOLES; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPINAL FRACTURES;

EID: 84887231202     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2013.813468     Document Type: Review

References (41)

1. Cummings SR, Kelsey JL, Nevitt MC, O'Dowd KJ. Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev 1985;7: 178-208.
2. Holbrook TL, Grazier KL, Kelsey JL, Stauffer RN. The frequency of occurrence, impact and cost of musculoskeletal conditions in the United States. Chicago, IL: American Academy of Orthopedic Surgeons; 1984.
3. EFFO and NOF. Who are candidates for prevention and treatment for osteoporosis Consensus Development Statement. Osteoporosis Int 1997;7:1-6.
4. Lindsay R, Burge RT, Strauss DM. One year outcomes and costs following a vertebral fracture. Osteoporosis Int 2005;16:78-85.
5. Kaptoge S, Armbrecht G, Felsenberg D, et al. When should the doctor order a spine X-ray Identifying vertebral fractures for osteoporosis care: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res 2004;19:1982-93.
6. Melton III LJ, Chrischilles EA, Cooper C, et al. Perspective. How many women have osteoporosis J Bone Miner Res 1992;7:1005-10.
7. Consensus Development Conference V. Diagnosis, prophylaxis, and treatment of osteoporosis. The A J Med 1993;94:646-50.
8. Kanis JA, Devogelaer JP, Gennari C. Practical guide for the use of bone mineral measurements in the assessment of treatment of osteoporosis: a position paper of the European foundation for osteoporosis and bone disease. The Scientific Advisory Board and the Board of National Societies. Osteoporosis Int 1996;6:256-61.
9. Guyatt GH. Evidence-based management of patients with osteoporosis. J Clin Densitom 1998;1:395-402.
10. Guyatt GH, Sinclair J, Cook DJ, Glasziou P. Users' guides to the medical literature: XVI. How to use a treatment recommendation. Evidence-Based Medicine Working Group and the Cochrane Applicability Methods Working Group. JAMA 1999;281:1836-43.
11. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary Control Clin Trials 1996;17:1-12.
12. Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions 4.2.6 [updated September 2006]. In: The Cochrane Library, Issue 4. Chichester, UK: John Wiley & Sons, Ltd.; 2006.
13. Chalmers I. The Cochrane collaboration: preparing, maintaining, and disseminating systematic reviews of the effects of health care. Ann Ny Acad Sci 1993;703:156-63; discussion 163-165.
14. Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses Lancet 1998;352:609-13.
15. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 1999;354:1896-900.
16. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
17. Cochrane GW. The combination of estimates from different experiments. Biometrics 1954;10:101-29.
18. Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med 2002;21:1539-58.
19. Black D, Delmas S, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. NEJM2007;356:1809-22.
20. Bone HG, Downs RW, Tucci JR, et al. Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers. J Clin Endocrinol Metab 1997;82:265-74.
21. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. New Engl J Med 1995;333:1437-43.
22. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41.
23. Greenspan SL, Parker RA, Ferguson L, et al. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res 1998;13:1431-8.
24. Lau EM, Woo J, Chan YH, Griffith J. Alendronate prevents bone loss in Chinese women with osteoporosis. Bone 2000;27:677-80.
25. McClung M, Clemmensen B, Daifotis A, et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med 1998;128:253-61.
26. Papapoulos SE, Quandt SA, Liberman UA, et al. Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporosis Int 2005;16:468-74.
27. Stevenson M, Jones ML, De Nigris E, et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005;9:1-160.
28. Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008;1:CD001155.
29. Cranney A, Wells G, Willan A, et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002;23: 508-16.
30. European Medicines Agency, 2009. Alendronate: summary of product characteristics. Available from http://www.emea.europa.eu [last accessed 19 Jun 2012].
31. Cryer B, Bauer DC. Oral biphosphanates and upper gastrointestinal tract problems: what is the evidence Mayo Clin Proc 2002;77: 1031-43.
32. Vestergaard P, Schwartz K, Pinholt EM, et al. Gastric and esophagus events before and during treatment of osteoporosis. Calcif Tissue Int 2010;86:110-5.
33. Chesnut III CH, McClung MR, Ensrud KE, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. AmJ Med 1995;99:144-52.
34. Tucci JR, Tonino RP, Emkey RD, et al. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 1996;101:488-501.
35. Shiraki M, Kushida K, Fukunaga M, et al. A placebo-controlled, single-blind study to determine the appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis. The Alendronate Research Group. Endocr J 1998;45:191-201.
36. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-82.
37. Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebocontrolled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study (Fosamax International Trial Study Group). Osteoporos Int 1999;9:461-8.
38. Bell NH, Bilezikian JP, Bone III HG, et al. Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women. J Clin Endocrinol Metab 2002;87:2792-7.
39. Greenspan SL, Schneider DL, McClung MR, et al. Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. Ann Intern Med 2002;136: 742-6.
40. Chailurkit LO, Jongjaroenprasert W, Rungbunnapun S, et al. Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis. J Bone Miner Metab 2003;21:421-7.
41. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. New Engl J Med 2007;357:1799-809.